Celltrion Inc.

Seung Suh Hong

Young Jun Park

Shin Jae Chang

Eun Joo Cho

Sung Jun Park

Kye Sook Yi

Young Mi Choi

Joon Hun Choi

Hyunnam Song

Jong-hyoup Lee

Jin-kyo Jeong

Jae Won Lee

Sung Hwan Kim

Ki Sung Kwon

Jung Yun Kim

Joo Hyuck Lim

So Jung Lee

Jin Kyo Jeong

Kyoung Suk Kim

Hyeong Mi Kim

Min Seob Lee

Yeon Jung Kim

Byung Pil Lim

Myung Sam Cho

Joon Woo Kim

Eun Beom Lee

Cheol Min Kim

Matthew Sangyup Lee

In-Suk Lee

Hwa Jin Lee

Seon Kyung Park

Ji Young Shin

Won Kang Moon

Jin Seo Lee

Joon Sun Yoon

Minseob Lee

Hyun Nam Song

Jin-Kyo Jeong

Jong-Hyoup Lee

The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus.

Composition comprising at least two influenza A virus-neutralizing-binding molecules

The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.

Epitope of hepatitis B virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis B virus

The present invention provides a stable peptide-conjugated, ascorbic acid derivative, a method for preparing the same, and a cosmetic composition comprising the same as an active ingredient. The stable peptide-conjugated ascorbic acid derivative of the present invention has both the effect of whitening the skin by inhibiting melanin production and the effect of reducing skin wrinkles by activating collagen production, and may be used in a cosmetic composition.

Stable peptide-conjugated ascorbic acid derivative, method for preparing same, and cosmetic composition comprising same

The present invention relates to an antibody-linker-drug conjugate in which an antibody and a cytotoxic drug are conjugated through an enzyme cleavable peptide linker capable of directly binding to a lysine residue of an antibody, a preparation method therefor, and

Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same

The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient.

Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same

Growing community of inventors

Seoul, South Korea

Seung Suh Hong